Fused Bicyclic Pyrimidones as WRN Inhibitors

The USPTO published patent application US20260098041A1 disclosing tricyclic pyrimidinone compounds as WRN inhibitors. The application includes claims directed to the compounds themselves, pharmaceutical compositions containing them, and methods of using them to treat cancer and infectious diseases. The inventors include Le Zhao, Yanran Ai, Marc Deller, and six others.\n\nFor entities in the pharmaceutical or oncology sectors, this publication establishes a priority date of February 26, 2025, for Incyte's WRN inhibitor technology. Competitors developing similar helicase inhibitors should review the claims for potential licensing needs or design-around considerations once the patent grants.